Cargando…
Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence
The molecular diversity of prostate cancer (PCa) has been demonstrated by recent genome-wide studies, proposing a significant number of different molecular markers. However, only a few of them have been transferred into clinical practice so far. The present study aimed to identify and validate novel...
Autores principales: | Daniunaite, Kristina, Bakavicius, Arnas, Zukauskaite, Kristina, Rauluseviciute, Ieva, Lazutka, Juozas Rimantas, Ulys, Albertas, Jankevicius, Feliksas, Jarmalaite, Sonata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201120/ https://www.ncbi.nlm.nih.gov/pubmed/34198725 http://dx.doi.org/10.3390/ijms22116091 |
Ejemplares similares
-
The utility of urine-circulating miRNAs for detection of prostate cancer
por: Stuopelyte, Kristina, et al.
Publicado: (2016) -
Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma
por: Kubiliute, Raimonda, et al.
Publicado: (2021) -
Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging
por: Bakavicius, Arnas, et al.
Publicado: (2019) -
The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival
por: Bakavičius, Arnas, et al.
Publicado: (2020) -
Frequent down-regulation of ABC transporter genes in prostate cancer
por: Demidenko, Rita, et al.
Publicado: (2015)